Late Acute Humoral Rejection in Low-Risk Renal Transplant Recipients Induced With an Interleukin-2 Receptor Antagonist and Maintained With Standard Therapy: Preliminary Communication

Simple item page
dc.contributor.authorMorales, J.
dc.contributor.authorContreras, L.
dc.contributor.authorZehnder, C.
dc.contributor.authorPinto, V.
dc.contributor.authorElberg, M.
dc.contributor.authorAraneda, S.
dc.contributor.authorHerzog, C.
dc.contributor.authorCalabran, L.
dc.contributor.authorAguilo, J.
dc.contributor.authorFerrario, M.
dc.contributor.authorBuckel, E.
dc.contributor.authorFierro, J. A.
dc.date.accessioned2024-01-10T13:14:19Z
dc.date.available2024-01-10T13:14:19Z
dc.date.issued2011
dc.description.abstractLow-risk renal transplant recipients treated with standard immunosuppressive therapy including interleukin-2 receptor (IL-2R) antagonist show a low incidence of early rejection episodes but few reports have examined the incidence and severity of late rejection processes. This study evaluated retrospectively cellular and antibody-mediated rejection (AMR) among 42 recipients selected because they showed low panel-reactive-antibodies, short cold ischemia time, no delayed graft function, and therapy including basiliximab (Simulect) induction. The mean observation time was 6.6 years. Sixty-seven percent of donors were deceased. Ten-year patient and death-censored graft survivals were 81% and 78%, respectively. Seven patients lost their kidneys due to nonimmunologic events. The seven recipients who experienced cellular rejection episodes during the first posttransplant year had them reversed with steroids. Five patients displayed late acute AMR causing functional deterioration in four cases including 1 graft loss. De novo sensitization occurred in 48% of recipients including patients without clinical rejection. In conclusion, long-term follow-up of kidney transplant recipients selected by a low immunologic risk showed a persistent risk of de novo sensitization evolving to acute AMR in 11% of cases. Although immunologic events were related to late immunosuppressive reduction, most graft losses were due to nonimmunologic factors.
dc.fechaingreso.objetodigital11-04-2024
dc.format.extent5 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.transproceed.2011.06.048
dc.identifier.issn0041-1345
dc.identifier.pubmedidMEDLINE:21839258
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2011.06.048
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78394
dc.identifier.wosidWOS:000294102000047
dc.information.autorucMedicina;Elberg M ;S/I;142541
dc.issue.numero6
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final2299
dc.pagina.inicio2295
dc.publisherELSEVIER SCIENCE INC
dc.revistaTRANSPLANTATION PROCEEDINGS
dc.rightsacceso restringido
dc.subjectNO INDUCTION
dc.subjectANTIBODY
dc.subjectBASILIXIMAB
dc.subjectSURVIVAL
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleLate Acute Humoral Rejection in Low-Risk Renal Transplant Recipients Induced With an Interleukin-2 Receptor Antagonist and Maintained With Standard Therapy: Preliminary Communication
dc.typeartículo
dc.volumen43
sipa.codpersvinculados142541
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-04-11. Late Acute Humoral Rejection in Low-Risk Renal Transplant Recipients Induced With an Interleukin-2 Receptor Antagonist and Maintained With Standard Therapy - Preliminary Communication.pdf
Size:
3.08 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas